How can small and medium-sized bio pharmaceutical enterprises win under the double ten law?

[market analysis of China Pharmaceutical network] biomedical industry is known as "the sunrise industry that will never decline" In recent years, with the development of life science, the improvement of people's living standard, the change of people's health concept and the acceleration of population aging, the biomedical industry in China has maintained a steady growth trend How can small and medium-sized bio pharmaceutical enterprises win under the double ten law? Photo source: Baidu photo) according to the data of China Business Industry Research Institute, the market scale of China's biopharmaceutical industry in 2015 was 145.3 billion yuan, accounting for 11.9% of China's pharmaceutical market From 2011 to 2015, the compound growth rate of market scale of China's bio pharmaceutical industry is 25.1%, which is growing rapidly in the three major areas of the pharmaceutical industry (chemical medicine, traditional Chinese medicine and bio medicine) However, behind the "never declining", long-term and high investment has become the pain that most biomedical enterprises are hard to touch China has become the second largest pharmaceutical consumer market in the world After years of development, China's pharmaceutical industry has gradually entered a more mature stage of development Both in terms of industrial production scale and sales market capacity, China has become one of the fastest growing industries in China According to dabei.com, there are nearly 5000 API and pharmaceutical enterprises in China, and the main business income of pharmaceutical manufacturing industry in 2016 is 2806.29 billion yuan, which is one of the few industries that exceeds the GDP growth rate Among them, nearly 50 pharmaceutical enterprises have passed the certification or inspection in Europe and the United States, and the export value of pharmaceutical manufacturing products exceeds 13.5 billion US dollars According to the data from the National Bureau of statistics, in the first half of 2017, China's pharmaceutical manufacturing industry achieved an operating revenue of 1463.67 billion yuan, an increase of 12.6% year on year; and a total profit of 159.63 billion yuan, an increase of 15.9% year on year On July 12, Wu Zhen, deputy director of the State Food and drug administration, attended the opening ceremony of the 2017 Seminar on drug quality management in developing countries, saying that after years of development, China has become the world's second largest pharmaceutical consumer market and large API exporter The market potential of domestic pharmaceutical industry has been explored continuously, especially in the field of biomedicine According to the data of China Business Industry Research Institute, the market scale of China's bio pharmaceutical industry in 2015 was 145.3 billion yuan, accounting for 11.9% of China's pharmaceutical market From 2011 to 2015, the compound growth rate of market scale of China's bio pharmaceutical industry is 25.1%, which is growing rapidly in the three major areas of the pharmaceutical industry (chemical medicine, traditional Chinese medicine and bio medicine) It is estimated that the market scale of China's biopharmaceutical industry will reach 33.3 billion yuan in 2020 Industry insiders pointed out that with the gradual release of relevant system dividends in the second half of the year, the approval of new drugs is expected to be significantly accelerated, and biomedical enterprises will usher in a new round of development opportunities Under the "double ten" law, how can small and medium-sized enterprises win? In the field of pharmaceutical innovation, there is a "double ten" law, that is, the research and development of an innovative drug takes ten years and costs one billion dollars This is also a big problem that puzzles the development of small and medium-sized pharmaceutical enterprises in China According to incomplete statistics of digebei.com, at present, there are 73 listed companies of biomedicine on the new third board As of the publication, 10 companies have disclosed the 2017 half year report The long cycle and high investment of new drug research and development make nearly half of the companies still in a loss state Among them, Binhui Biology (834925) had a revenue of 0 and a loss of 2.6351 million yuan in the first half of the year Binhui is a typical biomedical enterprise According to the data of digesin Sanban Research Institute, Binhui biology, relying on the technology of herpes simplex virus, mainly uses the core technologies such as virus construction, production process innovation, composite chromatography technology and preservation method innovation to carry out the research and development of anti-cancer drugs mainly based on the injection of recombinant oncolytic type II herpes simplex virus (oh2) Binhui Bio said in the semi annual report that the company's leading product, oh2, is currently in the clinical approval stage and is expected to enter the pharmaceutical market within three years Binhui biology was founded in 2010 According to its information, the company has invested 7 years in the research and development of the above drugs, and during this period, it has introduced three investors, i.e Borun investment, Guanggu venture capital and Sibao group According to digbeinet, Binhui biology has completed two rounds of financing since listing on the new third board at the end of 2015, with a total amount of 29 million yuan And there are many enterprises like Binhui biology on the new third board, which can't escape the "double ten" law, making them fall into a long wait How can they win in a market of 100 billion yuan? On August 17, Caibei new third board invested in the private board of directors biomedical field Caibei.com invites you to discuss rationally and calmly how small and medium-sized enterprises should solve difficult problems, seize opportunities and seize the market.